Targeting Breast Cancer: An Overlook on Current Strategies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 25

PMID 36835056

Authors

Domenico Iacopetta

Jessica Ceramella

Noemi Baldino

Maria Stefania Sinicropi

Alessia Catalano

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of cancer death among women worldwide. Globally, BC is the second most frequent cancer and first most frequent gynecological one, affecting women with a relatively low case-mortality rate. Surgery, radiotherapy, and chemotherapy are the main treatments for BC, even though the latter are often not aways successful because of the common side effects and the damage caused to healthy tissues and organs. Aggressive and metastatic BCs are difficult to treat, thus new studies are needed in order to find new therapies and strategies for managing these diseases. In this review, we intend to give an overview of studies in this field, presenting the data from the literature concerning the classification of BCs and the drugs used in therapy for the treatment of BCs, along with drugs in clinical studies.

Citing Articles

()-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation as Novel Antimitotic Agents Targeting Breast Cancer.

Ana G, Malebari A, Noorani S, Fayne D, OBoyle N, Zisterer D Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861179 PMC: 11769294. DOI: 10.3390/ph18010118.

Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation.

Ezzat A, Shafiek M, Shawki S, Abdel-Ghany S, Nazih M, Sabit H Sci Rep. 2025; 15(1):1824.

PMID: 39805861 PMC: 11730651. DOI: 10.1038/s41598-024-84744-y.

Apoptotic and Molecular Mechanisms of Carthamidin in Breast Cancer Therapy: An Integrated In Vitro and In Silico Study.

Palani S, Joseph J, Sridhar P, Bupesh G, Saravanan K, Chandrasekaran R Mol Biotechnol. 2024; .

PMID: 39704751 DOI: 10.1007/s12033-024-01331-2.

Probable Molecular Targeting of Inhibitory Effect of Carvacrol-Loaded Bovine Serum Albumin Nanoparticles on Human Breast Adenocarcinoma Cells.

Khodavandi P, Karami N, Khodavandi A, Alizadeh F, Kokhdan E, Zaheri A Chin J Integr Med. 2024; .

PMID: 39581936 DOI: 10.1007/s11655-024-4122-9.

Overview on Current Trends and Emerging Therapies in the Chemotherapy of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Qian J, Xu Y, Ling X, Wang F Galen Med J. 2024; 12:e3021.

PMID: 39464538 PMC: 11512434. DOI: 10.31661/gmj.v12i0.3021.

References

Fougner C, Bergholtz H, Norum J, Sorlie T . Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020; 11(1):1787. PMC: 7156396. DOI: 10.1038/s41467-020-15574-5. View

Risinger A, Riffle S, Lopus M, Jordan M, Wilson L, Mooberry S . The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation. Mol Cancer. 2014; 13:41. PMC: 4015978. DOI: 10.1186/1476-4598-13-41. View

Ihle C, Wright-Hobart S, Owens P . Therapeutics targeting the metastatic breast cancer bone microenvironment. Pharmacol Ther. 2022; 239:108280. DOI: 10.1016/j.pharmthera.2022.108280. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Ghaly H, Varamini P . New drug delivery strategies targeting the GnRH receptor in breast and other cancers. Endocr Relat Cancer. 2021; 28(11):R251-R269. DOI: 10.1530/ERC-20-0442. View

Sirohi B, Rastogi S, Dawood S . Buparlisib in breast cancer. Future Oncol. 2015; 11(10):1463-70. DOI: 10.2217/fon.15.56. View

Boer K . Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017; 9(7):465-479. PMC: 5502950. DOI: 10.1177/1758834017711097. View

Akinleye A, Avvaru P, Furqan M, Song Y, Liu D . Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013; 6(1):88. PMC: 3843585. DOI: 10.1186/1756-8722-6-88. View

Daly A, Rolph R, Cutress R, Copson E . A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer. Breast Cancer (Dove Med Press). 2021; 13:241-257. PMC: 8053601. DOI: 10.2147/BCTT.S268401. View

10.

Robertson J, Bondarenko I, Trishkina E, Dvorkin M, Panasci L, Manikhas A . Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016; 388(10063):2997-3005. DOI: 10.1016/S0140-6736(16)32389-3. View

11.

Royce M, Osgood C, Amatya A, Fiero M, Chang C, Ricks T . FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2021; 28(8):1487-1492. PMC: 9012688. DOI: 10.1158/1078-0432.CCR-21-3247. View

12.

Garcia-Fructuoso I, Gomez-Bravo R, Schettini F . Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. Curr Opin Oncol. 2022; 34(6):635-642. DOI: 10.1097/CCO.0000000000000892. View

13.

Abel M, Morgan T, Othieno A, Angeles A, Goldman M . Gynecological management of the breast cancer survivor. Best Pract Res Clin Obstet Gynaecol. 2022; 82:69-80. DOI: 10.1016/j.bpobgyn.2022.01.013. View

14.

Hu G, Wang D . Analysis of Cardiac Adverse Reactions Caused by Different Doses of Adriamycin Chemotherapy in Patients with Breast Cancer. J Healthc Eng. 2022; 2022:1642244. PMC: 8863445. DOI: 10.1155/2022/1642244. View

15.

Amiri-Kordestani L, Blumenthal G, Xu Q, Zhang L, Tang S, Ha L . FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014; 20(17):4436-41. DOI: 10.1158/1078-0432.CCR-14-0012. View

16.

Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L . Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects. Int J Mol Sci. 2020; 21(16). PMC: 7460580. DOI: 10.3390/ijms21165625. View

17.

Mitri Z, Constantine T, ORegan R . The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2013; 2012:743193. PMC: 3539433. DOI: 10.1155/2012/743193. View

18.

Cucciniello L, Gerratana L, Del Mastro L, Puglisi F . Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?. Cancer Treat Rev. 2022; 110:102445. DOI: 10.1016/j.ctrv.2022.102445. View

19.

Boszkiewicz K, Piwowar A, Petryszyn P . Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients-A Systematic Review and Meta-Analysis. J Clin Med. 2022; 11(11). PMC: 9181297. DOI: 10.3390/jcm11113133. View

20.

Buzun K, Bielawska A, Bielawski K, Gornowicz A . DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme Inhib Med Chem. 2020; 35(1):1781-1799. PMC: 7534307. DOI: 10.1080/14756366.2020.1821676. View